Thu Sep 19 06:23:15 UTC 2024: ## ImmunoPrecise Antibodies (IPA) Stock Receives Mixed Signals from Analysts

**Toronto, Canada, September 19, 2024** – ImmunoPrecise Antibodies (NASDAQ:IPA), a Canadian biotherapeutic research and technology company, has received mixed signals from analysts in recent weeks.

While HC Wainwright reiterated a “buy” rating and set a $9.00 price target on Tuesday, Benchmark reduced their price objective from $5.00 to $3.00 and issued a “speculative buy” rating on August 14th.

These differing opinions come amidst a recent earnings miss for ImmunoPrecise Antibodies. The company reported a loss of $0.52 per share in the second quarter, falling short of analysts’ estimates. Revenue also came in below expectations, reaching $4.76 million compared to an anticipated $4.92 million.

Despite the earnings miss, institutional investor Renaissance Technologies LLC increased their stake in the company by 70% in the second quarter, owning approximately 0.24% of ImmunoPrecise Antibodies’ stock.

ImmunoPrecise Antibodies specializes in NonaVac DNA technology for complex protein classes, including GPCRs and ion channels, and Rapid Prime technology for generating anti-idiotypic antibodies and producing monoclonal antibodies.

While the company faces challenges, the recent investment from Renaissance Technologies LLC suggests a positive outlook for the future. Investors will be watching closely as ImmunoPrecise Antibodies navigates these turbulent waters and seeks to capitalize on its innovative technologies.

Read More